Royal Marsden Hospital

Running trials

• Not yet recruiting

  A Study of LY4336619 in Adult Participants With Advanced Solid Tumors

  NCT07928258· Phase 1· Source

• Recruiting

  A Study of Short-course Hypofractionated Online-adaptive Radiotherapy for the Post-operative Treatment of Endometrial Cancer: Tolerability and Feasibility

  NCT07675733· Source

• Recruiting

  Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level

  NCT07649525· Phase 3· Source

• Recruiting

  Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

  NCT07486817· Phase 2· Source

• Recruiting

  Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

  NCT07621718· Phase 3· Source

• Recruiting

  RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

  NCT07413939· Phase 2/3· Source

• Recruiting

  Patient and Provider Perspectives on Genetic Risk Profiling

  NCT07741929· Source

• Recruiting

  A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

  NCT07365995· Phase 3· Source

• Recruiting

  DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy

  NCT07472517· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.

  NCT07440290· Phase 2/3· Source

• Recruiting

  A 2-part Phase 1/2 Open-label Trial on ODM-212

  NCT07563738· Phase 1/2· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)

  NCT07293351· Phase 1/2· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

  NCT07221149· Phase 2/3· Source

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Source

• Recruiting

  Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

  NCT07491445· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

  NCT07284849· Phase 3· Source

• Recruiting

  A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

  NCT07258511· Phase 3· Source

• Recruiting

  Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

  NCT07195695· Phase 3· Source

• Recruiting

  A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

  NCT07319871· Phase 1· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

  NCT07221357· Phase 2/3· Source

• Recruiting

  A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

  NCT07174336· Phase 3· Source

• Recruiting

  A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT07225946· Phase 3· Source

• Recruiting

  Assessing a Digital Exercise Intervention for Health Outcomes and Engagement in Regular Exercise

  NCT07243834· Source

• Recruiting

  A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract

  NCT07218380· Phase 3· Source

• Recruiting

  Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

  NCT07214779· Phase 3· Source

• Recruiting

  A Study of Clinical Outcomes in Participants With EGFR Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) in a Real-World Setting

  NCT07230691· Source

• Recruiting

  A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

  NCT07276399· Phase 3· Source

• Recruiting

  DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

  NCT05770544· Phase 2/3· Source

• Recruiting

  A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

  NCT07213674· Phase 3· Source

• Active, not recruiting

  A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

  NCT07288203· Phase 2· Source

• Recruiting

  A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

  NCT07186842· Phase 1/2· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Source

• Active, not recruiting

  A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)

  NCT07076121· Phase 2/3· Source

• Recruiting

  A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  NCT07213804· Phase 3· Source

• Recruiting

  A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

  NCT06988488· Phase 1/2· Source

• Recruiting

  A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

  NCT06989437· Phase 2/3· Source

• Recruiting

  Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

  NCT07106762· Phase 2/3· Source

• Recruiting

  This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

  NCT07028853· Phase 3· Source

• Recruiting

  A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

  NCT07111520· Phase 1/2· Source

• Recruiting

  A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

  NCT06919965· Phase 3· Source

• Recruiting

  A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

  NCT07164443· Phase 3· Source

• Recruiting

  A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

  NCT07070232· Phase 1/2· Source

• Recruiting

  Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer

  NCT06976892· Phase 1· Source

• Recruiting

  AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

  NCT07094113· Phase 1· Source

• Active, not recruiting

  UK ENcorafenib and BInimetinib Real-world Study in Melanoma

  NCT07022457· Source

• Recruiting

  A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

  NCT07082920· Phase 1· Source

• Recruiting

  A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

  NCT06863272· Phase 1/2· Source

• Recruiting

  The i4i PRODICT® Study: Evaluation of the i4i PRODICT® Test in Different Ethnic Groups (The i4i PRODICT® Study).

  NCT06636526· Source

• Recruiting

  A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

  NCT06941272· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer38 recruiting
• Childhood cancers27 recruiting
• Colorectal cancer26 recruiting
• Prostate cancer22 recruiting
• Gastric and esophageal cancer17 recruiting
• Ovarian cancer16 recruiting
• Pancreatic cancer15 recruiting
• Head and neck cancer11 recruiting
• Melanoma10 recruiting
• Sarcoma10 recruiting
• Bladder cancer9 recruiting
• Metastatic breast cancer8 recruiting
• Multiple myeloma8 recruiting
• Liver and biliary tract cancer7 recruiting
• Endometrial cancer6 recruiting
• Kidney cancer6 recruiting
• Neuroblastoma5 recruiting
• Acute lymphoblastic leukaemia3 recruiting
• Glioblastoma3 recruiting
• Hodgkin lymphoma3 recruiting
• Thyroid cancer3 recruiting
• Triple-negative breast cancer3 recruiting
• Acute myeloid leukemia2 recruiting
• Cervical cancer2 recruiting
• Chronic lymphocytic leukaemia2 recruiting
• Myelodysplastic syndromes2 recruiting
• Amyloidosis1 recruiting
• Chronic myeloid leukaemia1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Follicular lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Mesothelioma1 recruiting
• Myeloproliferative neoplasms1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers

  NCT06523803· Phase 1· Source

• Withdrawn

  A Trial of Gemcitabine, Pembrolizumab and IMM-101 as First Line Treatment in Patients With Metastatic Pancreatic Cancer

  NCT06498518· Phase 2· Source

• Completed

  Brightline-4: A Study to Test How Well Brigimadlin is Tolerated by People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT06058793· Phase 3· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· Source

• Completed

  A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer

  NCT05441501· Phase 1· Source

• Withdrawn

  177Lu-DTPA-Omburtamab Radioimmunotherapy for Leptomeningeal Metastasis From Solid Tumors (Breast, NSCLC, Malignant Melanoma)

  NCT04315246· Phase 1/2· Source

• Terminated

  ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

  NCT05358808· Phase 2· Source

• Completed

  A Study in Patients With BRAF V600E-mutant Metastatic Non-small Cell Lung Cancer (OCTOPUS)

  NCT05546905· Source

• Terminated

  A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)

  NCT05269355· Phase 2/3· Source

• Completed

  Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation

  NCT05198934· Phase 3· Source

• Completed

  A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

  NCT05249426· Phase 1· Source

• Completed

  A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

  NCT05323656· Phase 2· Source

• Completed

  Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

  NCT05218499· Phase 2/3· Source

• Completed

  A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

  NCT05002127· Phase 2/3· Source

• Terminated

  Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors

  NCT05228015· Phase 1· Source

• Completed

  A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2)

  NCT04907851· Phase 2· Source

• Completed

  A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

  NCT04907539· Phase 2· Source

• Completed

  A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck

  NCT04830592· Phase 1· Source

• Completed

  Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

  NCT04987203· Phase 3· Source

• Completed

  A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer

  NCT04702737· Phase 1· Source

• Completed

  A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.

  NCT04855929· Phase 1· Source

• Completed

  A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy

  NCT04660344· Phase 3· Source

• Completed

  Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)

  NCT04776148· Phase 3· Source

• Terminated

  HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

  NCT03850795· Phase 3· Source

• Completed

  Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer

  NCT04744831· Phase 2· Source

• Terminated

  A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

  NCT04501614· Phase 1/2· Source

• Terminated

  A Study of SGN-STNV in Advanced Solid Tumors

  NCT04665921· Phase 1· Source

• Completed

  A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

  NCT04543617· Phase 3· Source

• Completed

  A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer

  NCT04322539· Phase 3· Source

• Completed

  Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

  NCT04428151· Phase 2· Source

• Terminated

  A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment

  NCT04338269· Phase 3· Source

• Completed

  Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid Biopsies

  NCT04566614· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Source

• Terminated

  A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

  NCT04254107· Phase 1· Source

• Completed

  UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

  NCT04382664· Phase 2· Source

• Completed

  Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

  NCT04221945· Phase 3· Source

• Completed

  Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

  NCT04210115· Phase 3· Source

• Completed

  A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

  NCT04199104· Phase 3· Source

• Completed

  Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

  NCT04068181· Phase 2· Source

• Completed

  CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor

  NCT04145349· Phase 1/2· Source

• Terminated

  NOLA (NeuWave Observational Liver Ablation) Registry

  NCT04107766· Source

• Completed

  TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

  NCT04129502· Phase 3· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

  NCT05993299· Phase 2· Source

• Completed

  Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

  NCT06703346· Phase 2· Source

• Terminated

  PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)

  NCT04382898· Phase 1/2· Source

• Completed

  DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

  NCT04014075· Phase 2· Source

• Terminated

  A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

  NCT04032704· Phase 2· Source

• Completed

  Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)

  NCT04003636· Phase 3· Source

• Recruiting

  A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  NCT04104776· Phase 1/2· Source

Trial sites

• Royal Marsden Hospital5 trials
• The Royal Marsden Hospital1 trial
• The Royal Marsden Hospital Chelsea1 trial
• Royal Marsden Hospital (Site 0402)1 trial
• Royal Marsden Hospital1 trial
• Cancer Genetics Unit, Royal Marsden Hospital1 trial
• Head and Neck Unit, Royal Marsden Hospital1 trial
• Royal Marsden Hospital64 trials
• Royal Marsden Hospital (Chelsea)15 trials
• ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre (Site 2807)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA)-Gynaecology Research Centre (Site 4002)1 trial
• Royal Marsden Hospital - Chelsea, London1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA)-Lung Unit (Site 2075)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 0283)1 trial
• Royal Marsden Hospital - Chelsea (Site #0505)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 0701)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 1201)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 1403)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 1804)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 2606)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 2801)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 2806)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 3201)1 trial
• ROYAL MARSDEN HOSPITAL (CHELSEA) (Site 4006)1 trial
• Royal Marsden Hospital Department of Medicine1 trial
• Royal Marsden Hospital;Dept of Med-Onc1 trial
• Royal Marsden Hospital - Fulham5 trials
• Royal Marsden Hospital (Fulham Road)1 trial
• Royal Marsden Hospital - Fulham Road London (Site 0613)1 trial
• Royal Marsden Hospital - Fulham Road London (Site 1609)1 trial
• Royal Marsden Hospital - Institute of Cancer Research - Chelsea1 trial
• Royal Marsden Hospital - London12 trials
• Royal Marsden Hospital - London, Department of Medical Oncology1 trial
• Royal Marsden Hospital (Site 0536)1 trial
• Royal Marsden Hospital (Site 0902)1 trial
• Royal Marsden Hospital - site: Chelsea, London1 trial
• Royal Marsden Hospital - Surrey1 trial
• Royal Marsden Hospital (Sutton)16 trials
• Royal Marsden Hospital (Sutton)-Gynaecology Unit (Site 0696)1 trial
• Royal Marsden Hospital (Sutton)-Gynaecology Unit (Site 4010)1 trial
• Royal Marsden Hospital (Sutton) (Site 0741)1 trial
• Royal Marsden Hospital (Sutton) (Site 0800)1 trial
• Royal Marsden Hospital (Sutton) (Site 1407)1 trial
• Royal Marsden Hospital (Sutton) (Site 1409)1 trial
• Royal Marsden Hospital (Sutton) (Site 2076)1 trial
• Royal Marsden Hospital (Sutton) (Site 4005)1 trial
• The Royal Marsden Hospital29 trials
• The Royal Marsden Hospital, Chelsea10 trials
• The Royal Marsden Hospital - Chelsea Site1 trial
• The Royal Marsden Hospital, Fulham1 trial
• The Royal Marsden Hospital- London2 trials
• The Royal Marsden Hospitals1 trial
• The Royal Marsden Hospital - Surrey1 trial
• The Royal Marsden Hospital (Sutton and Chelsea)1 trial
• Royal Marsden Hospital1 trial
• Royal Marsden Hospital2 trials
• Royal Marsden Hospital - Surrey2 trials
• Royal Marsden Hospital - Sutton1 trial
• The Royal Marsden Hospital (Surrey)1 trial
• Cancer Genetics Unit, Royal Marsden Hospital1 trial
• Pharmacy: Royal Marsden Hospital1 trial
• Royal Marsden Hospital64 trials
• Royal Marsden Hospital Department of Medicine1 trial
• Royal Marsden Hospital - Drug Development Unit1 trial
• Royal Marsden Hospital;Institute of Cancer Research1 trial
• Royal Marsden Hospital (Site 0457)1 trial
• Royal Marsden Hospital (Site 0526)1 trial
• Royal Marsden Hospital. (Site 0901)1 trial
• Royal Marsden Hospital (Site 1510)1 trial
• Royal Marsden Hospital (Site 2904)1 trial
• Royal Marsden Hospital (Site 3347)1 trial
• Royal Marsden Hospital - site: Sutton, Surrey1 trial
• Royal Marsden Hospital - Surrey5 trials
• Royal Marsden Hospital (Sutton)23 trials
• Royal Marsden Hospital (Sutton)-Drug Development Unit (Site 1347)1 trial
• Royal Marsden Hospital (Sutton)-Gynaecology Unit (Site 2801)1 trial
• Royal Marsden Hospital (Sutton) (Site 0281)1 trial
• Royal Marsden Hospital (Sutton) (Site 0922)1 trial
• Royal Marsden Hospital (Sutton) (Site 2605)1 trial
• Royal Marsden Hospital (Sutton) (Site 2802)1 trial
• The Royal Marsden Hospital23 trials
• The Royal Marsden Hospital - Drug Development Unit2 trials
• The Royal Marsden Hospital - Neuro-Oncology Unit1 trial
• The Royal Marsden Hospital (Surrey)5 trials
• The Royal Marsden Hospital, Sutton9 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Prostate cancer66 works · 45 trials
• Sarcoma56 works · 20 trials
• Metastatic breast cancer27 works · 9 trials
• Kidney cancer26 works · 9 trials
• Multiple myeloma22 works · 19 trials
• Head and neck cancer16 works · 23 trials
• Neuroblastoma10 works · 7 trials
• Childhood cancers10 works · 46 trials
• Mesothelioma5 works · 5 trials